All the Active Ingredient Drugs
Xanthine Oxidase Inhibitor. Allopurinol 100 mg, 300 mg. TABS: 50 x 100mg, 20, 30 x 300mg.
Init.: 100 mg dly. Mild: 100-200 mg dly.
Moderat. sev.: 300-600 mg dly.
Sev.: 700-800 mg dly. If dosage on mg/
kg bdywght. basis is required, 2-10 mg/
kg bdywght./d. should be used.
Once dly. after a meal. Should the dly.
dosage exceed 300 mg and GI intoler.
be manifested, a divided doses regim.
may be appropr. The dosage should be
adjust. by monitor. serum urate
concentr. and urin. urate/uric acid
levels at appropr. interval. See lit.
Ped. popul.: child. <15 yrs. : 10 to 20
mg/kg bdywght./d. up to a max. of 400
mg dly. See lit.
Ren. impair. : In sev. renal impair. a
single doses of 100 mg at long. interv.
than one day is advised. If dialysis is
required 2 -3 times/wk. of 300-400 mg
immed. after each dialysis with none in
the interim.
Hep. impair.: Reduced doses should be
used in pts. with hep. impair. Period.
hep. funct. monitor. during the early
stages of ther. See lit.
Tmt. of high urate turnover condit.,
Dosage of Allopurinol should be at the
lower end of the recomm. dosage
schedule. See lit.
Manag. of pts. with signs & sympt. of
prim. or second. gout (acute attacks,
tophi, joint destruct., uric acid lithiasis
and/or nephrop.).
Manag.. of pts. with leukemia,
lymphoma, & malignan. who are receiv.
cancer ther. which causes elevat. of
serum & urin. uric acid levels.
Manag. of pts. with recur. calcium
oxalate calculi whose dly. uric acid excret. exceeds 800 mg/d. in male pts. and 750
mg/d in female pts.
Ther. in such pts. should be careful.
assessed init.and reassessed period.to
determ. in each case that tmt. is benefic.
and that the benefits outweigh the risks.
C/I: Hypersens.
